XtalPi and Pierre Fabre agree to AI-driven oncology drug discovery collaboration
Overview
XtalPi and Pierre Fabre announced on November 6, 2026 a collaboration agreement to jointly run several oncology R&D projects aimed at discovering new clinical drug candidates.
XtalPi will use its integrated AI and robotics platform to design and deliver novel small-molecule therapies against undisclosed targets. Pierre Fabre will select the most promising compounds and advance them through clinical and commercial development.
The deal includes an upfront payment, milestone payments and future revenue sharing. Financial terms were not disclosed.
Written by AI from the articles below · updated Nov 9, 4:52 AM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- LeiphoneNewsXtalPi and Pierre Fabre agree to AI-driven oncology drug discovery collaboration
AIXtalPi and Pierre Fabre announced on November 6, 2026 a collaboration agreement to jointly run several oncology R&D projects and discover new clinical drug candidates. XtalPi will use its integrated "AI+robotics" platform to design and deliver novel small-molecule therapies de novo against undisclosed targets, while Pierre Fabre will select and advance the most promising compounds through clinical and commercial development. The deal includes an upfront payment, milestone payments and future revenue sharing; financial terms were not disclosed.
Heat Trend
Not enough continuous observations to show a trend yet.